The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner - Wikidata - awgldk - TriplyDB

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

http://www.wikidata.org/entity/Q21629049

about

B-Raf and the inhibitors: from bench to bedside Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib Improved survival with vemurafenib in melanoma with BRAF V600E mutation The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Targeting melanoma by small molecules: challenges ahead Emerging targeted therapies for melanoma treatment (review)Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma Melanoma: from mutations to medicine Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization RAF inhibitors that evade paradoxical MAPK pathway activation A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy?Raf kinases in cancer-roles and therapeutic opportunities Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics From bench to bedside: lessons learned in translating preclinical studies in cancer drug development Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.A network-based method to evaluate quality of reproducibility of differential expression in cancer genomics studies Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Cutaneous side effects of vemurafenib: a case report and discussion.MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells Making sense of cancer genomic data.BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.

P2860

Q21198860-DCA5E03D-9D7A-4637-B3C9-354AF75A2500 Q24294914-864E1251-2D2B-4334-B33A-D4A899FE3C9F Q24303940-D3C5C0D2-3CF4-4392-85B1-FA5C0D772F97 Q24594790-EA021BC1-6DC2-4AA8-AD06-1A3FEC16EB77 Q24631953-DB71A90B-409E-4ACD-A783-81053369FC5C Q26744335-4046CD31-E783-4A47-A070-418DC428D226 Q26785930-5249A18F-5F00-42EE-A852-F0B533B16200 Q26824310-5B5CC64D-B680-4BF8-8EB5-649E1050B0F9 Q26824642-8D678C9C-6EA5-41BC-A904-A90AD03B4D4D Q26829997-68161BBC-4273-4FB2-B1DD-E3726F8B5FEF Q26853261-137625C7-9D72-4B5B-B739-65EBBC5CD7E5 Q27024061-C21C63A0-2660-409E-8D9B-B13CA221144C Q27026323-4D0B27BD-AA22-4F0A-A066-DCDE43118367 Q27678182-AC62A8F5-1FFA-4E98-AC35-619D83518C18 Q27702299-3247EF0A-8C93-4899-A975-745B8EBE7344 Q27852017-889404A5-DACB-4C82-B136-849BDA8F1DD7 Q27853105-816858F5-42CF-4D47-8B83-C3C44941EB3B Q28085240-015C6176-CE9D-4F5C-865D-36BC4283373F Q28237793-5FCA0EE0-DBB2-4B30-AE29-FEED04D76EB0 Q28265862-EE869B9C-321B-405D-951A-418AE8AE88BC Q28533949-28AEFB22-1AFD-42B2-8B45-22148612D74F Q28536351-01935F3F-A788-4B3E-9DA5-93F63A75FECD Q28541231-F3E4B436-0F01-42E9-AE10-C552CF603188 Q28543370-71095D3B-82DD-4E3F-B3D9-AB4BE9338552 Q28548486-22D8CE17-8829-4DF4-8430-9A1681CD15DE Q28602622-2EBD56AB-041C-4071-9E9E-CBEF05D0DD9C Q28603650-0EC9C9C0-C6EB-483F-9B24-A5BE41A3B2F6 Q28603655-4B47EAC0-E373-42FA-8D67-5AA558F1F8D1 Q29620033-487280B4-3662-4E11-9784-EDFCA532B8A8 Q30456779-92B356BE-0595-4C5F-82B1-7102255A5579 Q33566681-DA91247F-7034-469F-9020-7E8EDF8E02D4 Q33746514-C57DC936-68CE-4BAF-A046-70F452BCEF27 Q33808166-F9D6C27C-BCAF-4341-8F18-E24FBE0F8DB2 Q33824552-11F60CAC-3322-49DD-8EF6-15F3F7646248 Q33838195-F8F6F819-BBD0-484C-BBAB-47827B0B48B9 Q33846850-AA4A3C3B-0AD0-4345-B6B7-C5D418F681B0 Q33867475-433BE425-A995-4755-9E22-BC028E6DB3F4 Q33884726-65929B7D-3FF5-436C-8F3B-7CF24D44912F Q33909942-4CDBF2CD-DCB6-4749-A01D-FE9E9E220AB5 Q33971120-739A182C-3855-4D19-9482-A2E51405BCD8

P2860

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

http://www.wikidata.org/entity/Q21629049

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@ast

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@en

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@en-gb

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@nl

type

label

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@ast

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@en

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@en-gb

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@nl

prefLabel

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@ast

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@en

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@en-gb

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@nl

P1433

Q21629049-fbc9300b-4506-1bcf-f294-dc6df0beeaf2

P1476

Q21629049-94d7e56b-4acb-f138-ee0f-30e69bdeb659

P2093

Q21629049-0338F278-072A-44A9-81F3-8CB50DECF873

Q21629049-072034E3-F338-4B28-8DC1-EEF38BB11B8A

Q21629049-1F00115D-75BF-4CE1-8771-FD7DB2BE8931

Q21629049-2C52F3AB-01EA-4738-B809-8475B6C4B5F7

Q21629049-340C7FA9-E975-4777-873F-651EB3D5D57A

Q21629049-3CCEC965-6B29-4D91-BF28-6D6E0FE31CFE

Q21629049-3DA36860-7B91-424A-A514-AFB4A78DE73C

Q21629049-4ECEB556-CDB8-45B4-B1E1-2798D3DA6E53

Q21629049-8A20CDDE-4498-4FF9-9D83-80E1D716D81F

Q21629049-B7DEA4B6-03E2-48BF-B590-C732DC23485C

P2860

Q21629049-039E58ED-F59E-433F-B76C-E5E364A92CE4

Q21629049-07593647-70AA-4158-AA3B-8851DF27A070

Q21629049-08148053-623C-40E7-9E51-AB18A3D4388F

Q21629049-0CB1B687-9074-4FAC-9E14-BD730B9B8E0C

Q21629049-160F85B7-2569-44FB-8EBA-E9BFC007BD5D

Q21629049-1E19C39E-150D-43ED-8BDF-762F2756230C

Q21629049-2E50BBD2-107B-4750-ABCA-41EFD9DB37FE

Q21629049-317BD6A2-7995-41F8-91A4-C69E039F8958

Q21629049-38405CE5-5182-4DEF-842A-B614E4009323

Q21629049-44B28A53-6409-47D8-9050-4CFA5216DE80

P304

Q21629049-1f53cf4d-4094-63a7-917e-ac7297d6df50

P31

Q21629049-4b6263fa-4ae5-99ba-73a8-9d8cbb0a6ce4

P3181

Q21629049-B1B7DF1F-1F02-46F9-805F-F90D6F68DE25

P356

Q21629049-AD9D6787-7806-43D5-93B3-A02D85B942F3

P407

Q21629049-9301824B-8097-434A-9B9B-20C73B597413

P433

Q21629049-edbd3197-4c66-0ec7-5a3d-4241e6898915

P478

Q21629049-064ca87d-4ad2-346b-507d-b0ddcd0cbd38

P50

Q21629049-BB08EAB3-35C0-46D4-A65D-E96505246741

P577

Q21629049-f0cd8359-4a94-1db4-d56c-266a7005e97e

P5875

Q21629049-C91F3676-7D10-45A2-A91F-2EF536C63DA9

P698

Q21629049-783cc8af-4088-b8dd-e68f-81ccb2550fb6

P932

Q21629049-69caf03b-48f7-27b2-0bae-8613decf0510

P3181

P356

PNAS.1008990107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

The RAF inhibitor PLX4032 inhi ...... a V600E BRAF-selective manner

@en

P2093

Agnes Viale

http://www.w3.org/2001/XMLSchema#string

Barry S Taylor

http://www.w3.org/2001/XMLSchema#string

Christine A Pratilas

http://www.w3.org/2001/XMLSchema#string

David B Solit

http://www.w3.org/2001/XMLSchema#string

Ensar Halilovic

http://www.w3.org/2001/XMLSchema#string

Eric W Joseph

http://www.w3.org/2001/XMLSchema#string

Feng Xing

http://www.w3.org/2001/XMLSchema#string

James Tsai

http://www.w3.org/2001/XMLSchema#string

Madhavi Tadi

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism

Cluster analysis and display of genome-wide expression patterns

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Linear models and empirical bayes methods for assessing differential expression in microarray experiments

Mutations of the BRAF gene in human cancer

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

P304

14903–14908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

578283

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.1008990107

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45406610

http://www.w3.org/2001/XMLSchema#string

P698

20668238

http://www.w3.org/2001/XMLSchema#string

P932

2930420

http://www.w3.org/2001/XMLSchema#string